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Coronavirus 2019 disease (COVID-19) is caused by the virus SARS-CoV-2, transmissible
both person-to-person and from contaminated surfaces. Early COVID-19 detection among
healthcare workers (HCWs) is crucial for protecting patients and the healthcare workforce.
Because of limited testing capacity, symptom-based screening may prioritize testing and
increase diagnostic accuracy.
Methods and findings
We performed a retrospective study of HCWs undergoing both COVID-19 telephonic symp-
tom screening and nasopharyngeal SARS-CoV-2 assays during the period, March 9—April
15, 2020. HCWs with negative assays but progressive symptoms were re-tested for SARS-
CoV-2. Among 592 HCWs tested, 83 (14%) had an initial positive SARS-CoV-2 assay. Fifty-
nine of 61 HCWs (97%) who were asymptomatic or reported only sore throat/nasal conges-
tion had negative SARS-CoV-2 assays (P = 0.006). HCWs reporting three or more symp-
toms had an increased multivariate-adjusted odds of having positive assays, 1.95 (95% CI:
1.10–3.64), which increased to 2.61 (95% CI: 1.50–4.45) for six or more symptoms. The
multivariate-adjusted odds of a positive assay were also increased for HCWs reporting fever
and a measured temperature� 37.5˚C (3.49 (95% CI: 1.95–6.21)), and those with myalgias
(1.83 (95% CI: 1.04–3.23)). Anosmia/ageusia (i.e. loss of smell/loss of taste) was reported
less frequently (16%) than other symptoms by HCWs with positive assays, but was associ-
ated with more than a seven-fold multivariate-adjusted odds of a positive test: OR = 7.21
(95% CI: 2.95–17.67). Of 509 HCWs with initial negative SARS-CoV-2 assays, nine had
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symptom progression and positive re-tests, yielding an estimated negative predictive value
of 98.2% (95% CI: 96.8–99.0%) for the exclusion of clinically relevant COVID-19.
Conclusions
Symptom and temperature reports are useful screening tools for predicting SARS-CoV-2
assay results in HCWs. Anosmia/ageusia, fever, and myalgia were the strongest indepen-
dent predictors of positive assays. The absence of symptoms or symptoms limited to nasal
congestion/sore throat were associated with negative assays.
Introduction
Coronavirus 2019 disease (COVID-19) has become pandemic since being first reported in
China [1]. COVID-19 can present along a clinical spectrum from asymptomatic, mild symp-
toms (e.g. cold-like) [2–4], influenza-like (e.g. fever, malaise and myalgia) to severe lower
respiratory disease with dyspnea and pneumonia [3–5]. Evidence supports person-to-person
transmission, including from asymptomatic patients [6–9]. Severe acute respiratory syndrome
coronavirus-2’s (SARS-CoV-2) environmental persistence suggests transmission may also
result from hand contact with contaminated surfaces [10] followed by facial self-
contamination.
Healthcare workers (HCWs) potentially experience greater risks for emerging infectious
diseases [11–13] due to occupational exposure to sick patients and virus-contaminated sur-
faces [14]. Contagious HCWs may infect patients, co-workers and family members. Moreover,
the removal of ill HCWs from duty can threaten essential healthcare staffing during an epi-
demic [15]. Therefore, infection prevention and quick, accurate diagnosis of potential
COVID-19 in HCWs are crucial to maintaining hospital operations [16].
Testing HCWs with early/mild symptoms has been approved and prioritized [17,18].
Because they are more likely to be tested, characterization of HCWs’ presentations and viral
assays provide valuable clinical and epidemiologic perspectives on COVID-19, to compare
with hospitalized patients generally representing more severe cases [19]. There is no reference
diagnostic test for COVID-19. Currently available tools are symptom reports and a reverse
transcriptase polymerase chain reaction (RT-PCR) assay that detects SARS-CoV-2 RNA from
naso-/oropharyngeal specimens [20], but whose test characteristics are not established at this
time [21]. Because of limited testing capacities, and potential latency of up to 14 days in illness
onset from exposure [22], HCW testing is largely restricted to persons reporting compatible
symptoms [17,18]. Nonetheless, many HCWs and other first responders desire wider testing
because of potential exposures, often without symptoms. Therefore, we investigated the pre-
senting symptoms most predictive of positive/negative SARS-CoV-2 RT-PCR results among
HCWs.
Methods
Study population and setting
Since March 9, 2020, the occupational health service of a Massachusetts community healthcare
system has implemented a staff “hotline” system to maintain a viable/healthy workforce and
operational continuity during the pandemic. Accordingly, the service was re-configured to
perform telephonic triage of HCWs for COVID-19-related concerns; electronically document
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related clinical information; manage and communicate pandemic-related testing results; and
oversee HCWs’ safe return to work.
Reasons for contacting the COVID-19 hotline have included: a) travel; b) potential
contact with a COVID-19-positive/suspect person; and/or c) possible viral symptoms. A stan-
dard triage form (S1 File) was completed by occupational nursing and medical personnel
based on contemporaneous telephonic interviews with each HCW. The form contains demo-
graphics, administrative information, potential exposure history, and eleven potential viral
symptoms: fever (subjective, as well as highest measured temperature), cough (new or worse),
shortness of breath (new or worse), myalgia, malaise, sore throat, nasal symptoms (including
runny nose, sneezing, congestion, and sinus symptoms), gastrointestinal symptoms (including
nausea, vomiting, and diarrhea), rash, anosmia/ageusia (i.e. loss of smell/loss of taste), and
headache. Headache and anosmia/ageusia were added to a revised form after several HCW
reports.
In accordance with expert guidelines [17,18], symptomatic HCWs were referred for SARS--
CoV-2 testing (see below). Employees tested elsewhere forwarded their RT-PCR results to the
occupational health service and were triaged via a telephonic visit. In this retrospective cohort
study, we included all adult employees/personnel or contractors of the hospital who had
undergone both COVID-19-related triage and a SARS-CoV-2 PCR assay between March 9
and April 15, 2020.
Specimen collection and testing
SARS-CoV-2 assays were performed at designated sites, where trained healthcare system staff
collected nasopharyngeal swabs and transferred each specimen to a 3ml vial with viral trans-
port media (VTM), Universal Transport Media (UTM) or saline. After collection, specimens
were refrigerated at 2–8˚C, unless transported immediately, and refrigerated at 2–8˚C during
transport. HCWs samples were sent to one of three laboratories (the Massachusetts Depart-
ment of Public Health (MADPH), a commercial lab, or a tertiary hospital partner), whichever
offered the fastest turnaround-time on the day of testing. All three laboratories used real-time,
reverse-transcriptase–polymerase-chain-reaction (RT-PCR) diagnostic panels for the qualita-
tive detection of nucleic acid from the 2019 SARS-CoV-2 (MADPH, CDC 2019-Novel
RT-PCR; commercial laboratory, Roche Cobas SARS-CoV-2; and hospital partner, Abbott
Real Time SARS-CoV-2). The limit of detection at the laboratories testing the majority of our
samples was 100 copies of viral RNA/ml. Positive assay results represented detection of SARS--
CoV2 RNA, while for negative results, the virus was not detected. In case of an invalid or inde-
terminate result, a repeat sample is requested.
Data collection
For operational needs, the occupational health service maintains data from the triage encoun-
ters, PCR results and clinical/work status on a secure “live” spreadsheet. The presence/absence
of the eleven possible symptoms, travel, and exposure history in the spreadsheet entries were
verified from triage forms by an occupational medicine physician for every HCW undergoing
a RT-PCR assay. For body temperature, we recorded the highest value before testing as self-
reported by each HCW. SARS-CoV-2 PCR assay results for HCWs tested outside of the health-
care system were verified and entered in the database.
Because there is no reference diagnostic test, we considered false negative SARS-CoV-2
assays as occurring when the initial test was negative, but symptoms had progressed/persisted
at telephonic follow-up and a repeat assay was subsequently SARS-CoV-2 positive.
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Human subjects
The Institutional Review Board of the healthcare system reviewed the study protocol, deter-
mined it to be exempt and waived informed consent based on the use of existing, HIPAA-dei-
dentified data. Prior to statistical analyses, all data were deidentified and transferred to a
spreadsheet without linkages to the “live” database.
Statistical analysis
Continuous characteristics were presented as means and standard deviations and compared
between groups with the parametric t-test. Categorical variables were presented as counts and
percentages and compared between groups using the chi-square test of independence with the
Yates’ continuity correction or the Fisher’s exact test, as appropriate. No imputations were
made for missing data.
Principal component analysis (PCA) was utilized to identify dominant symptoms (those
contributing more than 5% variability to the identified principal component explaining most
data variability). Logistic regression models were then fit to evaluate symptom association with
the probability of having a positive SARS-CoV-2 assay, after age-, sex- and other symptom
adjustment. Regression results are provided as odds ratios (ORs) and corresponding 95% con-
fidence intervals (CIs). The Hosmer-Lemeshow goodness of fit test with 15 groups was also
performed to check the model fit. Additionally, the C-statistic was calculated to assess each
model’s predictive accuracy.
The clinical COVID-19 attack rate during the study period was calculated as: (the number
of initial positive SARS-CoV-2 assays + the number of false negatives) divided by the system’s
estimated total HCW population (n = 4600). COVID-19 complication rates were calculated as
HCWs who required an emergency room visit or hospitalization before the end of the study
period (April 15, 2020) and/or had intubation or death before the end of follow-up (April 20,
2020); divided by the number of total COVID-19-diagnosed HCWs.
Statistical analyses were conducted using the R software (version 3.6.3). All tests were two-
sided and a P-value< 0.05 was considered statistically significant.
Results
Demographic and clinical characteristics
During the study period, we identified 592 unique HCWs who underwent triage and SARS--
CoV-2 RT-PCR. Eighty-three (14.0%) had positive SARS-CoV-2 RT-PCR results on the initial
assay. The cohort’s presentation at triage is summarized in Table 1. The average age was
43.6 ± 12.9 years old, with no significant difference between HCWs testing positive or negative
(P = 0.84). The proportion of men with positive tests (27.7%) was non-significantly higher
than among those with negative tests (20.0%) (P = 0.15).
SARS-CoV-2 positive HCWs self-reported several symptoms more frequently than those
with negative assays: fever (55% vs. 27%), myalgia (57% vs. 35%), headache (41% vs. 28%), and
anosmia/ageusia (16% vs. 3%) (all P<0.05). Nasal symptoms (runny, sneezing, congestion,
sinus) were more frequently associated with negative assays (52% vs. 35%) (P = 0.006)
(Table 1, Fig 1).
Among HCWs reporting fever, 87% (40/46) of those testing SARS-CoV-2 positive and
89% (121/136) of those testing negative had measured their body temperature. The mean peak
temperature reported was higher in HCWs with a positive assay (38.0 ± 0.7˚C) compared to
those with negative assays (37.6 ± 0.7˚C) (P = 0.006). Dichotomizing the peak temperature
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(� or<37.5˚C), the measured temperature exceeded the threshold in 85% of HCWs with posi-
tive RT-PCR, compared to 56% of those with negative assays (P = 0.002).
Symptoms and probabilities of positive SARS-CoV-2 assay
Assay results for asymptomatic or mildly symptomatic HCWs are shown in Table 2. None of
the HCWs with only sore throat and/or nasal symptoms had a positive SARS-CoV-2 assay
(0%), while all 34 (100%) had a negative PCR (P = 0.009). When we combined asymptomatic
and mildly symptomatic HCWs, 59/61 (97%) had negative initial assays (P = 0.006).
Total symptoms at triage ranged from zero to ten, with only 40 (7%) HCWs reporting
seven or more symptoms. Table 3 shows the counts and percentages of HCWs with positive
and negative assays, and age- and sex-adjusted odds ratios for increasing numbers of total
reported symptoms. HCWs workers reporting three or more symptoms had an increased like-
lihood of a positive SARS-CoV-2 assay (OR = 1.95 (95% CI: 1.10–3.64). The odds ratio of a
positive RT-PCR generally increased with additional symptoms and reached 2.61 (95% CI:
1.50–4.45) for six or more symptoms.
Further multivariate logistic regression analyses of PCA-determined dominant symptoms
are shown in Table 4. HCWs reporting fever had an age- and sex-adjusted odds ratio of 3.34
(95% CI: 2.07–5.41) of having a positive SARS-CoV-2 assay, which remained significant after
additional adjustment for other symptoms (OR = 2.88, 95% CI: 1.66–5.01). When measured
body temperature�37.5˚C was considered together with reported fever, the odds of a positive
SARS-CoV-2 assay increased to 4.47 (95% CI: 2.66–7.48) in the age- and sex-adjusted model
and to 3.49 (95% CI: 1.95–6.21) in the all-symptom-adjusted model. The odds ratios remained
similar when the body temperature threshold changed to 38˚C (OR = 4.45, 95% CI: 2.30–8.44
in the age- and sex-adjusted model; OR = 2.85, 95% CI: 1.36–5.86 in the full model).
HCWs reporting anosmia/ageusia had an increased age- and sex- adjusted odds ratio of
6.50 (95% CI: 2.89–14.51), and multivariate odds ratio of 7.21 (95% CI: 2.95–17.67) of having a
positive SARS-CoV-2 assay. Myalgia was also associated with increased odds ratios of having a
Table 1. Symptom and body temperature distributions at time of triage among healthcare workers (HCWs) by SARS-CoV-2 test results.
Overall (N = 592) Positive (N = 83) Negative (N = 509) P value
Age 43.6 (12.9) 43.9 (12.7) 43.6 (12.9) 0.843
Female 467 (78.9%) 60 (72.3%) 407 (80.0%) 0.149
Fever 182 (30.7%) 46 (55.4%) 136 (26.7%) <0.001
Measured Temperature (˚C) 37.68 (0.71) (n = 161) 37.95 (0.69) (n = 40) 37.60 (0.69) (n = 121) 0.006
Temperature� 37.5˚C 102 (63.4%) (102/161) 34 (85.0%) (34/40) 68 (56.2%) (68/121) 0.002
Cough 365 (61.7%) 59 (71.1%) 306 (60.1%) 0.074
Shortness of breath 111 (18.8%) 14 (16.9%) 97 (19.1%) 0.747
Myalgia 225 (38.0%) 47 (56.6%) 178 (35.0%) <0.001
Malaise 274 (46.3%) 47 (56.6%) 227 (44.6%) 0.055
Sore throat 320 (54.1%) 38 (45.8%) 282 (55.4%) 0.131
Nasal symptoms (runny, sneezing, congestion, sinus) 293 (49.5%) 29 (34.9%) 264 (51.9%) 0.006
Gastrointestinal symptoms (nausea/ vomiting/ diarrhea) 151 (25.5%) 20 (24.1%) 131 (25.7%) 0.856
Rash 10 (1.7%) 3 (3.6%) 7 (1.4%) 0.154a
Anosmia/Ageusia 27 (4.6%) 13 (15.7%) 14 (2.8%) <0.001
Headache 175 (29.6%) 34 (41.0%) 141 (27.7%) 0.020
Mean (SD) for age and body temperature, count (percentage) for all other variables.
a Based on Fisher’s exact test.
https://doi.org/10.1371/journal.pone.0235460.t001
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positive SARS-CoV-2 assay in both models: OR = 2.41 (95% CI: 1.50–3.89) and OR = 1.83
(95% CI: 1.04–3.23), respectively. Headache was a significant predictor in the age- and sex-
adjusted model: OR = 1.84 (95% CI: 1.13–2.96), but not in the all-symptom-adjusted model.
Nasal congestive symptoms were a significant negative predictor in both multivariate mod-
els: OR = 0.51 (95% CI: 0.31–0.82) and OR = 0.40 (95% CI: 0.23–0.68), respectively.
Fig 1. Symptom distributions among HCWs with initial SARS-CoV-2 (the virus causing COVID-19) testing results. The symptoms shaded in salmon-red are the
symptoms more frequently seen with positive tests, and the symptoms shaded in blue-green are more frequently seen with negative tests. GI symptom denotes a
gastrointestinal symptom (nausea/ vomiting/ diarrhea). Nasal symptom includes runny nose, sneezing, congestion, and sinus symptoms. No/mild symptom denotes no
symptom or only sore throat and/or nasal symptoms. The asterisks above the bars denote different statistically significance levels when comparing HCWs with positive
assays and HCWs with negative assays (�: P<0.05, ��: P<0.01, ���: P<0.001).
https://doi.org/10.1371/journal.pone.0235460.g001
Table 2. SARS-CoV-2 test results in asymptomatic healthcare workers (HCWs) and HCWs with only nasal/throat
symptoms.
Positive (N = 83) Negative (N = 509) P value a
No symptom 2 (2.4%) 25 (4.9%) 0.406
Only sore throat 0 (0%) 12 (2.4%) 0.390
Only nasal symptoms 0 (0%) 7 (1.4%) 0.601
Only sore throat and/or nasal symptoms 0 (0%) 34 (6.7%) 0.009
No symptom or Only sore throat and/or nasal symptoms 2 (2.4%) 59 (11.6%) 0.006
a Fisher’s exact test
https://doi.org/10.1371/journal.pone.0235460.t002
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The Hosmer-Lemeshow goodness of fit test for all models demonstrated no evidence of
poor fit. Therefore, we also present C statistics (i.e. area under the curve) for each symptom in
Table 4. After age- and sex-adjustment, fever had the best discrimination between HCWs with
positive and negative SARS-CoV-2 assays (C-statistic = 0.663).
Estimated false negatives, negative predictive value, attack and
complication rates
Nine HCWs with symptom progression after an initial negative SARS-CoV-2 assay are
described in S1 Table. Upon re-testing, all nine had positive RT-PCR for SARS-CoV-2. These
cases represent 1.8% of originally negative HCWs (9/509), yielding an estimated negative pre-
dictive value of 98.2% (95% CI: 96.8–99.0%) for excluding clinically relevant COVID-19
disease.
The cumulative attack rate for clinically symptomatic COVID-19 during the study period
(March 9-April 15, 2020) was 92 incident cases among an estimated employee cohort of 4600
Table 3. SARS-CoV-2 test results by number of symptoms reported at triage a.
Positive (N = 83) Negative (N = 509) Age and sex adjusted OR (95% CI)
< 2 symptoms 7 (8.4%) 71 (13.9%) 0.57 (0.23–1.20)
� 2 symptoms 76 (91.6%) 438 (86.1%) 1.77 (0.83–4.36)
� 3 symptoms 68 (81.9%) 357 (70.1%) 1.95 (1.10–3.64)
� 4 symptoms 53 (63.9%) 238 (46.8%) 2.00 (1.24–3.28)
� 5 symptoms 35 (42.2%) 152 (29.9%) 1.72 (1.06–2.77)
� 6 symptoms 24 (28.9%) 69 (13.6%) 2.61 (1.50–4.45)
Abbreviations: OR, odds ratio; CI, confidence interval.
a The whole list of symptoms reported were fever, cough, shortness of breath, myalgia, malaise, sore throat, nasal
symptoms (runny, sneezing, congestion, sinus), gastrointestinal symptoms (nausea/ vomiting/ diarrhea), rash,
anosmia/ageusia (i.e. loss of smell/loss of taste), and headache.
https://doi.org/10.1371/journal.pone.0235460.t003











Fever 46 (55.4%) 136 (26.7%) 3.34 (2.07–5.41) 0.663 2.88 (1.66–5.01)
Fever plus temperature� 37.5˚C a 33 (39.8%) 65 (12.8%) 4.47 (2.66–7.48) 0.660 3.49 (1.95–6.21)c
Myalgia 47 (56.6%) 178 (35.0%) 2.41 (1.50–3.89) 0.625 1.83 (1.04–3.23)
Malaise 47 (56.6%) 227 (44.6%) 1.58 (0.99–2.55) 0.575 1.08 (0.60–1.92)
Shortness of breath 14 (16.9%) 97 (19.1%) 0.85 (0.44–1.54) 0.539 0.66 (0.32–1.28)
Nasal symptoms (runny, sneezing, congestion,
sinus)
29 (34.9%) 264 (51.9%) 0.51 (0.31–0.82) 0.601 0.40 (0.23–0.68)
Gastrointestinal symptoms (nausea/ vomiting/
diarrhea)
20 (24.1%) 131 (25.7%) 0.91 (0.52–1.54) 0.538 0.54 (0.28–1.00)
Headache 34 (41.0%) 141 (27.7%) 1.84 (1.13–2.96) 0.572 1.43 (0.82–2.47)
Anosmia/ageusia 13 (15.7%) 14 (2.8%) 6.50 (2.89–14.51) 0.588 7.21 (2.95–17.67)
Abbreviations: OR, odds ratio; CI, confidence interval; ROC curve, receiver operating characteristic curve.
a HCWs not measuring their temperature were assumed to not have elevated body temperature as a sensitivity analysis
b Adjusted for age, sex, and all symptoms, i.e. fever, cough, shortness of breath, myalgia, malaise, sore throat, nasal symptom (runny, sneezing, congestion, sinus),
gastrointestinal symptom (nausea/ vomiting/ diarrhea), rash, anosmia/ageusia (i.e. loss of smell/loss of taste), and headache
c Adjusted for all variables as above except fever
https://doi.org/10.1371/journal.pone.0235460.t004
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or 2.0% (95% CI: 1.6–2.5%). A total of nine among the 92 incident HCW COVID-19 cases
(9.8%) (all nine diagnosed with the initial PCR assay) experienced a complication during the
study period: four required an emergency room visit, five needed hospitalization, two of the
hospitalized required intubation, and one of those died (1.1%).
Discussion
This original investigation describes initial symptoms and their associations with SARS-CoV-2
RT-PCR assays among all 592 HCWs in our system tested between March 9 and April 15,
2020. Overall, we tested 13% of our workforce, which is a testing rate 6.7-fold greater than that
of the Massachusetts population during the same period [23]. We found that a total of 16%
(including 14% with initial positive assays and 2% with initial false negative assays) of these
HCWs were diagnosed with clinical COVID-19, yielding a cumulative attack rate of 2% for
our workforce.
The absence of symptoms or those limited to the throat/nose (excluding anosmia/ageusia)
were significantly associated with having negative SARS-CoV-2 assays. In contrast, HCWs
reporting three or more symptoms had 2-fold greater age- and sex-adjusted odds of having
positive assays. These odds generally increased for each additional symptom reported, reach-
ing 2.6-fold for six or more symptoms. Our results are consistent with previous reports sug-
gesting that RT-PCR results correlate with viral shedding, COVID-19 symptom onset and
clinical severity [24,25]. In multivariate adjustment models, HCWs with anosmia/ageusia had
higher than seven-fold odds of having positive RT-PCR; those with fever and a measured
temperature� 37.5˚C had almost 3.5-fold odds of having positive RT-PCR; and those with
myalgia had almost 2-fold odds of having positive assays, while nasal symptoms were associ-
ated with a 60% reduced risk of a positive assay.
Studies support varying clinical manifestations among COVID-19 patients [2–5]. An inves-
tigation of critically ill cases found half presenting with temperature� 38˚C during their ICU
stay, while more than 80% had cough and/or shortness of breath, accompanied by tachypnea
[19]. In contrast, a study of subclinical COVID-19 patients showed 40% of cases initially pre-
sented fever and non-specific symptoms, such as cough and sore throat, but none exhibited
dyspnea [4]. Regarding HCWs, it is useful to compare our results with two recent HCW series,
which reported average ages (42–43 years-old) and female predominance (73–77%) similar to
ours. In the large US national series, 78% of HCWs with COVID-19 had cough, 68% had fever,
66% reported myalgia, and 41% presented shortness of breath [26]. In the second smaller series
from King County, WA (USA), the most common initial symptoms were cough (50%), fever
(42%) and myalgias (35%) [27]. In general agreement, our HCW COVID-19 cases commonly
reported fever (55%), myalgia (57%) and cough (71%), but only 17% reported dyspnea. How-
ever, only our investigation collected data on those testing negative as well, demonstrating that
cough is a very non-specific symptom that was also reported by 60% of those testing negative.
On the other hand, fever (particularly if measured) and myalgia were independent predictors
of positive SARS-CoV-2 assays, as were anosmia/ageusia in HCWs symptomatic for longer
periods. Regarding the latter findings, they are in accordance with a cross-sectional study of
the general population, which reported adjusted odds ratios for COVID-19 of 6.6 and 3.1 for
anosmia/ageusia and fever, respectively [28], similar to our findings of fully-adjusted odds of
7.2 and 3.5 for the same symptoms. In our study, anosmia/ageusia was reported less frequently
(16%) as compared to 59% in the cross-sectional study, most likely because our symptoms
reports were captured early in the course of illness.
Our results are also comparable to a Dutch study examining the point prevalence of positive
SARS-CoV-2 RT-PCRs among HCWs with mild respiratory symptoms, during the early
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outbreak in the Netherlands, finding 4% of HCWs across nine hospitals positive, ranging from
0–10% for each individual hospital [14]. We found an overall positive initial test rate of 14%
during a five-week period, which overlapped early spread with a later surge in community
transmission and hospital COVID-19 traffic. We have observed that the proportion of positive
tests increased along with epidemic’s progression in our region.
False negative results of SARS-CoV-2 RT-PCR have been reported at rates from 10–30%
[21,29]. We did find nine HCWs who initially tested negative, developed progressive symp-
toms and had subsequent positive RT-PCR. None of these likely false-negatives were among
the HCWs with the most severe cases requiring emergency/hospital care. Further study of
symptomatic patients, their household contacts and of random population samples with both
RT-PCR and serologies [30] are needed to better elucidate the true prevalence of asymptomatic
carriers as well as the frequency of false negative RT-PCRs. Nonetheless, our estimated nega-
tive predictive value of 98% for excluding clinically relevant COVID-19 disease is very reassur-
ing regarding the test’s performance when done properly.
Our findings have potential implications for HCW COVID-19 surveillance. First, HCWs
with no symptoms or mild symptoms limited to sore throat/nasal congestion and a measured
body temperature lower than 37.5˚C, have a low probability of a positive RT-PCR and
COVID-19. Thus, many HCWs with no symptoms or symptoms more compatible with allergy
or a common cold could refrain from testing and continue to self-monitor symptoms and
body temperature. In contrast, early systemic symptoms, especially fever and myalgia are pre-
dictive of possible clinical COVID-19, while anosmia/ageusia are fairly specific later findings.
Our results support expert guidelines for temperature monitoring [18], which should not be
limited to healthcare settings, and that a measured temperature� 37.5˚C may be predictive of
a positive SARS-CoV-2 RT-PCR result.
Our study does have some limitations. First, the HCWs tested were not a random or conve-
nience sample, but rather all HCWs who self-reported COVID-19-related concerns. Thus, our
results do not necessarily reflect total cumulative incidence of COVID-19 among HCWs in our
healthcare system. However, our triage and testing process were conducted in accordance with
expert guidelines [3,17,18], and therefore, our results can inform other healthcare systems
employing comparable protocols. Second, because there is no reference diagnostic test for
COVID-19, the test performance characteristics of the RT-PCR are not established [21]. Poten-
tially corroborating serology tests were not available during the study period, but may be helpful
in the future to identify additional infections that occurred with mild or no symptoms [30].
Our study also has several strengths. First, HCWs generally reported their symptoms at tri-
age before their SARS-CoV-2 PCR test results were available, eliminating recall bias. Second,
all symptoms reports were validated by occupational medicine physicians, strengthening their
accuracy. Third, all HCWs had complete symptom and testing data. Moreover, unlike other
HCW studies, we used identical methods to collect data on persons testing negative and were
able to compare these two groups. In addition, all HCWs tested had telephonic follow-up vis-
its, allowing us to identify and re-test HCWs with potential false negative results. Finally, our
present study included all eligible employees in the healthcare system. The study population
comprised not only healthcare professionals but also staff/contractors such as maintenance or
IT (Information Technology) persons. Therefore, our results may be generalized to other
working populations during the pandemic.
Conclusions
Among HCWs, systemic symptoms/signs (fever, body temperature� 37.5˚C, myalgia, and
headache) and anosmia/ageusia were predictive of positive SARS-CoV-2 assays, with fever,
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anosmia/ageusia, and myalgia being the strongest independent predictor. In contrast, no
symptoms or isolated sore throat/nasal congestion were associated with negative SARS-CoV-2
assays.
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